. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug;60(2):260-4. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

  1. One of an interesting set of articles that deals with the proteasome inhibition model of Parkinson disease first described by McNaught and colleagues [1]. This model was met with a large amount of enthusiasm when first reported; however, there has been much contention in the field over the reproducibility of the phenotype.

    This issue of Annals includes a message from the editor (Stephen Hauser) who should be commended not only for the quote leading his piece ("When we hear news we should always wait for the sacrament of confirmation.") but also for encouraging an open discourse on this controversial topic within the pages of Annals. In addition to a nice piece by Drs. Beal and Lang, there are articles by McNaught and Olanow, Zeng et al., Schapira et al., Manning Bog et al., Kordower et al., and Bove et al. all discussing this model or variations thereof. Although the final message seems to be that the model is not reproducible among laboratories, it is clear that not all issues have been fully resolved.

    References:

    . Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol. 2004 Jul;56(1):149-62. PubMed.